Cite
MLA Citation
Keke Fei et al.. “IBI379, a novel B cell maturation antigen/CD3 bispecific T-cell engager, displays high antitumor efficacy in preclinical models of multiple myeloma.” Cancer letters, vol. 536, 2022, p. . http://access.bl.uk/ark:/81055/vdc_100153446316.0x000043